This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Mikhail Kosiborod
Saint Luke’s Health System, Kansas City, MO, USA

Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, Professor of Medicine at the University of Missouri-Kansas City and the inaugural recipient of the Ben McCallister, MD Endowed Chair in Cardiovascular Research at Saint Luke’s Health System. 


Dr. Kosiborod is an internationally-recognized expert in the field of cardiometabolic disease and has authored and co-authored more than 350 peer-reviewed publications. Dr. Kosiborod has conducted and led numerous national and international clinical trials, many of which have had a significant impact on treatment guidelines and clinical practice. Dr. Kosiborod’s body of work has been central to the elucidation of the impact of SGLT2 inhibition in improving cardiovascular outcomes and survival in various clinical settings, perhaps one of the most important advances in clinical cardiology seen in a generation.


Carolyn Lam

Duke-National University, Singapore, Singapore

Dr Lam is a Professor at Duke-National University of Singapore and Senior Consultant at the National Heart Centre Singapore specializing in heart failure and recognized globally for expertise in heart failure with preserved ejection fraction. She is a world-renown clinical trialist, with her work as part of the global steering committee of the PARAGON and EMPEROR-Preserved trials contributing to the first FDA-approved treatment for HFpEF to date (Entresto Wins First FDA Nod in Hard-to-Treat Type of Heart Failure ( as well as the first robustly positive outcomes trial in HFpEF to date. Her leadership in the field is recognized in her appointment to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force. She is a recipient of the NMRC Senior Investigator Clinician Scientist Award, Programme Lead of A*STaR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), Principal Investigator of ASIAN-HF (multinational study across 11 Asian countries), and Executive Committee member/ lead of multiple global clinical trials. She has published >350 articles in journals including NEJM, JAMA, Lancet, Circulation, and European Heart Journal; and has been recognized in the Clarivate Highly cited Researcher 2021 in the field of Clinical Medicine( and as a World Expert by Expertscape’s PubMed-based algorithms (top 0.1%of scholars writing about Heart Failure over the past 10 years; Heart Failure: Worldwide - She serves as Associate Editor for Circulation and the European Journal of Heart Failure. Dr Lam is heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of “Body and Soul” by MediaCorp Singapore.

Read full bio